The Role of CTLA-4 in T Cell Exhaustion in Chronic Hepatitis B Virus Infection

被引:3
作者
Apol, Asa Didriksen [1 ,2 ,3 ,4 ]
Winckelmann, Anni Assing [1 ,3 ,4 ]
Duus, Rasmus Buelow [1 ]
Bukh, Jens [1 ,3 ,4 ]
Weis, Nina [1 ,2 ]
机构
[1] Copenhagen Univ Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, DK-2200 Copenhagen, Denmark
[3] Copenhagen Univ Hosp, Dept Infect Dis, Copenhagen Hepatitis C Program CO HEP, DK-2650 Hvidovre, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Copenhagen Hepatitis C Program CO HEP, DK-2200 Copenhagen, Denmark
来源
VIRUSES-BASEL | 2023年 / 15卷 / 05期
关键词
T cell exhaustion; CTLA-4; chronic hepatitis B; immune checkpoint inhibitors; PD-1; IMMUNOPATHOGENESIS; BLOCKADE; CD28;
D O I
10.3390/v15051141
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Patients with chronic hepatitis B (CHB) gradually develop T cell exhaustion, and the inhibitory receptor molecule, cytotoxic T-lymphocyte antigen-4 (CTLA-4), may play a role in this phenomenon. This systematic review investigates the role of CTLA-4 in the development of T cell exhaustion in CHB. A systematic literature search was conducted on PubMed and Embase on 31 March 2023 to identify relevant studies. Fifteen studies were included in this review. A majority of the studies investigating CD8(+) T cells demonstrated increased expression of CTLA-4 in CHB patients, though one study found this only in HBeAg-positive patients. Three out of four studies investigating the expression of CTLA-4 on CD4(+) T cells found upregulation of CTLA-4. Several studies showed constitutive expression of CLTA-4 on CD4(+) regulatory T cells. CTLA-4 blockade resulted in heterogeneous responses for all T cell types, as it resulted in increased T cell proliferation and/or cytokine production in some studies, while other studies found this only when combining blockade of CTLA-4 with other inhibitory receptors. Although mounting evidence supports a role of CTLA-4 in T cell exhaustion, there is still insufficient documentation to describe the expression and exact role of CTLA-4 in T cell exhaustion in CHB.
引用
收藏
页数:14
相关论文
共 34 条
  • [1] [Anonymous], 2015, Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, DOI DOI 10.3969/J.ISSN.1674-7380.2015.03.001
  • [2] Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation
    Bengsch, Bertram
    Martin, Bianca
    Thimme, Robert
    [J]. JOURNAL OF HEPATOLOGY, 2014, 61 (06) : 1212 - 1219
  • [3] Adaptive immunity in HBV infection
    Bertoletti, Antonio
    Ferrari, Carlo
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S71 - S83
  • [4] CTLA-4 interferes with the HBV-specific T cell immune response (Review)
    Cao, Hui
    Zhang, Ruiwen
    Zhang, Wei
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 (02) : 703 - 712
  • [5] HBV-Induced Immune Imbalance in the Development of HCC
    Chen, Yongyan
    Tian, Zhigang
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [6] Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis
    Cho, Hyosun
    Kang, Hyojeung
    Lee, Hwan Hee
    Kim, Chang Wook
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
  • [7] CTLA4 gene polymorphism and autoimmunity
    Gough, SCL
    Walker, LSK
    Sansom, DM
    [J]. IMMUNOLOGICAL REVIEWS, 2005, 204 : 102 - 115
  • [8] Exhausted phenotype of circulating CD8+ T cell subsets in hepatitis B virus carriers
    Jiang, Daixi
    Chen, Can
    Yan, Danying
    Zhang, Xiaobao
    Liu, Xiaoxiao
    Yan, Dong
    Cui, Dawei
    Yang, Shigui
    [J]. BMC IMMUNOLOGY, 2022, 23 (01)
  • [9] The study of immune checkpoint inhibitors in chronic hepatitis B virus infection
    Li, Siyu
    Li, Na
    Yang, Shanru
    Deng, Haiyan
    Li, Yanguo
    Wang, Yixuan
    Yang, Jiaqiang
    Lv, Jiaxin
    Dong, Lan
    Yu, Guansen
    Hou, Xin
    Wang, Geng
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 109
  • [10] Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1136/bmj.n160, 10.1016/j.ijsu.2021.105906]